The study titled "A Phase I/II Study of Burixafor Plus Fludarabine
and Cytarabine in Adults With Relapsed or Refractory Acute Myeloid Leukemia (AML) " is an open-label study to determine the safety and efficacy of burixafor in combination with two chemotherapeutic agents, fludarabine
and cytaribine and will enroll up to 15 patients.
A 47-year-old male underwent NMA allo-SCT (using fludarabine
and total body irradiation (TBI) 1200 cGyl) from an HLA-identical sibling due to high-risk acute myeloblastic leukemia (AML).
A repeat bone marrow biopsy performed two months later was consistent with lymphoma and 2 more cycles of fludarabine
therapy were initiated.
The new agent was approved specifically for patients with CLL that has not responded to fludarabine
(Fludara) and alemtuzumab (Campath).
The research team also involving researchers from University of Sienna, Italy have found PBOX- 15 was more effective than the current medication, fludarabine
, used to treat the disease and also killed CLL cells that were resistant to treatment.
Tests in the laboratory show the drug is equally effective in treating the cells of patients who respond poorly to the current treatment, fludarabine
About half of the patients (59) in the study were refractory to both fludarabine
The drug is currently not approved for the treatment of multiple sclerosis but is indicated for treating B-cell chronic lymphocytic leukemia in patients who have been treated with alkylating agents and who have failed fludarabine
3) The patient in our case was immune-compromised from fludarabine
chemotherapy followed by high-dose prednisone therapy.
A humanized monoclonal antibody for treating B-cell chronic lymphocytic leukemia in people who have been treated with alkylating agents and have failed treatment with fludarabine
The drug, called Campath, slows the growth of cancerous white blood cells and is used to help patients whose condition has failed to improve with an existing treatment called Fludarabine
We describe a patient with B-CLL whose B cells expressed CD8, a predominantly T-cell marker also expressed in natural killer cells, and we propose that patients with this uncommon feature of B-CLL might have an increased sensitivity to fludarabine
phosphate, a substance recently often used to treat patients with CLL.